Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Clovis Oncology enters $175mm financing agreement to help pay for Rubraca combo trials

Executive Summary

Clovis Oncology Inc. entered into a non-dilutive financing agreement with TPG Sixth Street Partners, the proceeds of which will reimburse the company for a clinical trial evaluating its ovarian cancer drug Rubraca (rucaparib) with Opdivo (nivolumab). (Clovis and BMS entered into a trial collaboration for the combo therapy in 2017.)
Deal Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement
    • Nonconvertible Debt

Related Companies